- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.04. | H.C. Wainwright reiterates Inhibikase stock rating on trial progress | 2 | Investing.com | ||
| 07.04. | Inhibikase: Erster Patient in Phase-3-Studie für Lungenhochdruck-Medikament aufgenommen | 2 | Investing.com Deutsch | ||
| 07.04. | Inhibikase startet Phase-3-Studie für Lungenhochdruck-Medikament mit erstem Patienten | 2 | Investing.com Deutsch | ||
| 07.04. | Inhibikase enrolls first patient in Phase 3 PAH drug trial | 1 | Investing.com | ||
| INHIBIKASE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 07.04. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.04. | Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 26.03. | Inhibikase Therapeutics GAAP EPS of -$0.49 | 1 | Seeking Alpha | ||
| 26.03. | Inhibikase Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.03. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 26.03. | Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity | 307 | GlobeNewswire (Europe) | WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
| 21.01. | BofA Securities initiates coverage on Inhibikase stock with Buy rating | 6 | Investing.com | ||
| 29.12.25 | Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path | 3 | Investing.com | ||
| 29.12.25 | Jefferies bekräftigt Kaufempfehlung für Inhibikase-Aktie wegen beschleunigtem FDA-Verfahren | 8 | Investing.com Deutsch | ||
| 26.12.25 | Inhibikase: H.C. Wainwright startet Coverage mit "Buy" und 385 % Kurspotenzial | 3 | Investing.com Deutsch | ||
| 26.12.25 | H.C. Wainwright assumes coverage on Inhibikase stock with Buy rating | 3 | Investing.com | ||
| 19.12.25 | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.11.25 | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.11.25 | Inhibikase Therapeutics sells 68.97M shares and pre-funded warrants at $1.45/share | 1 | Seeking Alpha | ||
| 21.11.25 | Inhibikase Therapeutics prices $100 million public offering | 1 | Investing.com | ||
| 21.11.25 | Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants | 2 | GlobeNewswire (USA) |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 180,75 | +0,33 % | AbbVie Canada: AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec | National competition, in collaboration with adMare BioInnovations, demonstrates AbbVie's commitment to a thriving biotech ecosystem in Quebec.Award provides RIME Therapeutics with a year of laboratory... ► Artikel lesen | |
| TEVA | 29,500 | -1,34 % | Teva Pharmaceutical: Teva's 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets | Teva exceeded all sustainability-linked bond targets, linking financial performance to expanded patient access to medicines and reduced environmental impact.Through its global access to medicines programs... ► Artikel lesen | |
| EYEPOINT | 11,000 | -2,65 % | EyePoint, Inc.: EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026 | ||
| ORGANIGRAM GLOBAL | 1,178 | -2,32 % | Organigram Global Inc.: Organigram Closes Previously Announced Acquisition of Sanity Group, Private Placement Financing with BAT and ATB Senior Secured Credit Facilities | Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram") and Sanity Group GmbH ("Sanity" or "Sanity Group") jointly announced the successful closing of Organigram's previously... ► Artikel lesen | |
| QUANTUM BIOPHARMA | 4,564 | -6,63 % | Quantum BioPharma Provides Corporate Update | THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, April 27, 2026... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 72,54 | +0,11 % | Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares | SAN FRANCISCO, April 23, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology... ► Artikel lesen | |
| AMARIN | 12,100 | +1,68 % | Amarin Corporation plc: Amarin Reports 2026 First Quarter Financial Results | Total Revenue Increased Led by Higher International Sales Generated Positive Cash Flow and Reiterates Expectation for Full Year Positive Cash Flow Recently Updated Industry Guidelines Expand Global... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 3,600 | -3,74 % | Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors | Achieve Names Two New Exemplary Healthcare Leaders to its Board of Directors New Leadership and Financing, up to $354 Million ($180 Million Upfront and $174 Million Dependent on the Exercise of Milestone... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 173,50 | +0,32 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA | Prescription Drug User Fee Act (PDUFA) date set for August 25, 2026
For U.S. media and investors only
DUBLIN, April 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 4,240 | +0,71 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update | - Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events - - First Patient Dosed in Phase 2 Trial of... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 442,80 | +0,48 % | MADRIGAL PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| XORTX THERAPEUTICS | 2,262 | -6,55 % | XORTX Therapeutics Inc.: XORTX Meets Nasdaq Continued Listing Requirements | CALGARY, Alberta, April 21, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 61,17 | +0,96 % | BridgeBio Pharma, Inc.: BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET | ||
| OPUS GENETICS | 4,240 | -2,30 % | Citizens initiates Opus Genetics stock coverage with outperform rating | ||
| RIGEL PHARMACEUTICALS | 25,190 | +2,19 % | Rigel Pharmaceuticals: Warum diese kleine Biotech-Aktie plötzlich kaum zu ignorieren ist | Rigel Pharmaceuticals rückt nach einem Strategiewechsel, einer gestrafften Kostenbasis und einem Portfolio mit mehreren Wachstumstreibern wieder in den Fokus spekulativ orientierter Investoren. Die... ► Artikel lesen |
INHIBIKASE THERAPEUTICS INC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 1,875 Euro und damit -0,79 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBIKASE THERAPEUTICS INC finden Sie auf Wallstreet Online.